https://orcid.org/0000-0002-8574-3297
References
- Jost WH. Therapie des idiopathischen Parkinson-Syndroms. Bremen: Unimed-Verlag; 2020.
- Antonini A, Jost WH, Levodopa- I. Apomorphin-Infusion zur Therapie motorischer Komplikationen bei fortgeschrittener Parkinson-Krankheit. Fortschr Neurol Psychiatr. 2018;86:S5–S9.
- Sudmeyer M, Ebersbach G, Holtmann M, et al. Practical use of the levodopa pump. Fortschr Neurol Psychiatr. 2016;84:404–410.
- Reddy P, Martinez-Martin P, Rizos A, et al. Intrajejunal levodopa versus conventional therapy in parkinson disease: motor and nonmotor effects. Clin Neuropharmacol. 2012;35:205–207.
- Vijiaratnam N, Hewer S, Varley S, et al. Levodopa‐carbidopa intestinal gel: is the naso‐jejunal phase a redundant convention? Intern Med J. 2018;48:469–471.
- Fernandez HH, Standaert DG, Hauser RA, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month, open-label results. Mov Disord. 2015;30:500–509.
- Jost WH. Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration. Expert Opin Drug Saf. 2014;13(4):447–458.
- LP AB. Lecigon intestinal gel ENG SmPC. (2021)
- Senek M, Nielsen EI, Nyholm D. Levodopa-entacapone-carbidopa intestinal gel in Parkinson’s disease: a randomized crossover study. Mov Disord. 2017;32:283–286.
- Senek M, Nyholm D, Nielsen EI. Population pharmacokinetics of levodopa gel infusion in Parkinson’s disease: effects of entacapone infusion and genetic polymorphism. Sci Rep. 2020;10:18057.
- Othman M, Widman E, Nygren I, et al. Initial Experience of the levodopa-entacapone-carbidopa intestinal gel in clinical practice. J Pers Med. 2021;11:254.
- Jost W, Dafsari H, Ebersbach G, et al. P 81 ELEGANCE – a prospective non-interventional study of the long-term effectiveness and safety of levodopa–entacapone–carbidopa intestinal gel (LECIG) in patients with advanced Parkinson’s disease in routine care. Clin Neurophysiol. 2022;137:e61.